Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is indicated to dilate the pupil. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil (1 ). FDA label
Also known as phenylephrine HCl, Children's Sudafed PE Nasal Decongestant Liquid
phenylephrine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | phenylephrine |
| Name | Type | Description |
|---|---|---|
| phenylephrine HCl | DRUG | A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule |
Inclusion Criteria: * Male and female children and adolescents, ages 2 to \< 18 years, with a minimum weight of 24 pounds will be eligible to participate. In addition, each subject will be \> 5th percentile and \< 95th percentile for weight based on age and gender. * Subjects will have a body mass ...
Top 1 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150 |
Phenylephrine is studied for rhinitis, a condition involving nasal inflammation and congestion. It is a small molecule developed by Johnson & Johnson (ticker JNJ). The clinical program in rhinitis has focused on pediatric pharmacokinetics rather than large efficacy trials.
Phenylephrine targets the alpha-1 adrenergic receptors ADRA1A, ADRA1B, and ADRA1D, where it acts as an agonist. By activating these receptors it produces vasoconstriction, which is the pharmacological basis for its use in nasal congestion associated with rhinitis.
Johnson & Johnson, which trades under the ticker JNJ, is the developer associated with phenylephrine. The company is linked to the clinical development program for this small molecule in rhinitis.
Phenylephrine is in Phase 1 clinical development for rhinitis. The program has one completed Phase 1 trial, and no active trials are currently listed. It is an investigational asset in this development context rather than a newly approved product.
Phenylephrine has been studied in NCT00762567, a completed Phase 1 pediatric pharmacokinetic study in rhinitis. The trial enrolled 36 participants in the United States, included ages 2 years and older, and was uncontrolled, with no randomization or blinding.
Yes, phenylephrine HCl is another name for phenylephrine. The HCl designation refers to the hydrochloride salt form of the same small molecule, so searches for either name refer to the same active ingredient and the same clinical development program.